NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Temozolomide (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms the MAYA Study
Most Recent Events
- 01 Apr 2022 Status changed from active, no longer recruiting to completed.
- 08 Mar 2022 Results published in the Journal of Clinical Oncology
- 23 Sep 2021 Planned primary completion date changed from 1 Feb 2021 to 30 Sep 2021.